Clinical Trial Update: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial update reporting safety and anti-leukemic activity of vodobatinib (K0706) in Ph+ chronic myeloid leukemia patients resistant or intolerant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Vodobatinib (Vodobatinib)

Snippet

Sponsor: Sun Pharma Advanced Research Company Limited | Conditions: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING